About enGene

51-200 employees View all
7171 Frederick Banting,St-Laurent,Quebec,CA
enGene Inc. is a biotechnology company developing a proprietary non-viral gene therapy platform for localized delivery of nucleic acid payloads to mucosal tissues. The dually derived chitosan (DDX) platform has a high-degree of payload flexibility including DNA and various forms of RNA (siRNA, shRNA, lncRNA etc.) with broad tissue and disease applications. In addition to developing EG-70 for BCG-unresponsive NMIBC, enGene enGene is developing unique genetic medicines for respiratory indications. The company is also evolving its technology to enable applications in several mucosal tissues such as the nasal and genital mucosa as well as the gastrointestinal tract among others. enGene is supported financially by top-tier institutional investors including Forbion Capital Partners, Fonds de Solidarité FTQ, Pharmstandard International S.A., Lumira Capital and Johnson & Johnson Development Corporation.

enGene Alternatives

Frequently Asked Questions about enGene

What is enGene email format?

The widely used enGene email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.

What is enGene customer service number?

To contact enGene customer service number in your country click here to find.

Who is the CEO of enGene?

Jason D Hanson is the CEO of enGene. To contact Jason D Hanson email at [email protected] or [email protected].

Supercharge your
Prospecting &
Outreach with
Supercharge your Prospecting &
Outreach with ContactOut

Search Portal

Find countless prospects outside of LinkedIn fast

Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.

Discover the source of our data

Learn more